Bio-rad Laboratories Inc (BIO) Q2 2016 10-Q Quarterly Earnings

Short answer

Bio-rad Laboratories Inc (BIO) filed its Q2 2016 10-Q quarterly report on Aug 5, 2016 for the quarter ended Jun 30, 2016.

AI summary of MD&A and risk factor updates

Q2 revenue $516.8M, up 2.1% YoY from $506.1M
Gross margin 54.2% vs 55.2% YoY; net income margin 3.5% vs 5.6%
Life Science best segment, sales $180.0M, up 5.5%; Clinical Diagnostics sales $333.7M, up 0.5%
Cash, equivalents and short-term investments $791.6M; operating cash flow $69.7M for six months vs $68.0M
Restructuring charge $11.7M; capital expenditures $56.9M, with ERP project costs projected at $175M

Regulatory risk: EU draft in vitro diagnostic rules, Russia and China labeling changes, creating uncertain approvals and compliance costs
Legal risk: FCPA settlement compliance obligations through November 2016, with potential DOJ or SEC action for violations
Operational risk: Third ERP deployment may repeat prior delays that disrupted manufacturing, logistics and sales
Market risk: Foreign subsidiaries generated 62% of net sales, exposing results to dollar strengthening
Financial risk: $434.4 million outstanding debt and $200.0 million revolving facility, constrained by leverage and interest-coverage covenants

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Compare quarters, check guidance or see what insiders and funds did around the report.